Navigation Links
Human Genome Sciences to Sponsor Conference Call

ROCKVILLE, Md., March 9 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it will sponsor a conference call to discuss the results of its ACHIEVE 1 Phase 3 trial of Albuferon(R) (albinterferon alfa-2b) in patients with genotype 1 chronic hepatitis C.

(Logo: )

The conference call will be hosted by senior management and will be held on Monday, March 9, 2009 at 8:15 am Eastern Time.

Investors may listen to the call by dialing 888-270-6751 or 913-981-5518, confirmation code 4076361, five to 10 minutes before the start of the call. A replay of the conference call will be available within a few hours after the call ends. Investors may listen to the replay by dialing 888-203-1112 or 719- 457-0820, confirmation code 4076361.

This conference call also will be webcast and may be accessed at Investors interested in listening to the live webcast should log on before the conference call begins in order to download any software required. The archive of the conference call will remain available for several days.

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs.

HGS and Human Genome Sciences are trademarks of Human Genome Sciences, Inc.


This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials, the Company's ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with facilities, intense competition, the uncertainty of patent and intellectual property protection, the Company's dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, while the Company has begun shipment of ABthrax to the U.S. Strategic National Stockpile, the Company will continue to face risks related to acceptance of future shipments and FDA's approval of the Company's Biologics License Application for ABthrax, if and when it is submitted. If the Company is unable to meet requirements associated with the ABthrax contract, future revenues from the sale of ABthrax to the U.S. Government will not occur. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Human Genome Sciences to Sponsor Conference Call to Discuss Full Year 2008 Financial Results
2. Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes
3. China Biologic Products High-Purity Human Albumin Research and Development Project to be Listed in the National Torch Plan
4. 14th Annual Wharton Health Care Business Conference to Feature CEOs from WebMD, McKesson, Humana and Given Imaging
5. Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the Worlds First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop
6. ArunA Biomedical Announces Commercial Release of its Human Embryonic Stem Cell Derived Neural Cells
7. Modigene Awarded Second-Year Grant by Israeli Government to Support Development of Its Longer-Acting Human Growth Hormone
8. Victhom Human Bionics Neurobionix Division receives ISO 13485:2003 Certification for its Design Control System
9. MultiVu Video Feed: Geron Receives FDA Clearance to Begin Worlds First Human Clinical Trial of Embryonic Stem Cell-Based Therapy
10. Rules-Based Medicine, Inc. Launches Human Kidney Damage Biomarker Panel
11. Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C
Post Your Comments:
(Date:12/1/2015)... FRANCISCO , Dec. 1, 2015  Twist Bioscience, a ... Emily Leproust , Ph.D., has been selected as one ... 2015 for fast-tracking the building blocks of life . ... Global Thinkers whose contributions and work have changed lives ... --> "It is an honor to be recognized ...
(Date:12/1/2015)... SAN DIEGO , Dec. 1, 2015 /PRNewswire/ ... that uses allogeneic stem cells for cardiovascular indications, ... clinical trial protocol based on recommendations from a ... leaders and its Scientific Advisory Board members ... boards analyzed preliminary Phase IIa safety and efficacy ...
(Date:12/1/2015)... Cepheid (Nasdaq: CPHD ) today announced ... Jaffray Healthcare Conference in New York City ... its outlook for the fourth quarter of 2015 and ... longer term business model expectations. John Bishop ... to be the fastest growing company of the major ...
(Date:11/30/2015)... ... November 30, 2015 , ... Global ... practitioners and aesthetics professionals from Central America and abroad for the first Iberoamerican ... City, Panama Feb. 17-19, 2016. Testart will present and discuss new trends in ...
Breaking Biology Technology:
(Date:11/9/2015)... JOSE, Calif. , Nov. 9, 2015  Synaptics ... human interface solutions, today announced broader entry into the ... vehicle-specific solutions that match the pace of consumer electronics ... and biometric sensors are ideal for the automotive industry ... vehicle. Europe , ...
(Date:10/29/2015)... Oct. 29, 2015   MedNet Solutions , an ... spectrum of clinical research, is pleased to announce that ... Association (MHTA) as one of only three finalists for ... – Small and Growing" category. The Tekne Awards honor ... shown superior technology innovation and leadership. ...
(Date:10/29/2015)... ANN ARBOR, Mich. , Oct. 29, 2015 ... with Eurofins Genomics for U.S. distribution of its ... DNA-seq kit and Rubicon,s new ThruPLEX Plasma-seq ... DNA to enable the preparation of NGS libraries ... in plasma for diagnostic and prognostic applications in ...
Breaking Biology News(10 mins):